Mibefradil withdrawn from the market.
Billups
S J
SJ
Carter
B L
BL
D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D020748:Mibefradil; D011358:Product Surveillance, Postmarketing; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil